


## HIGHLIGHTS Q3 2010



Good Performance

- Overall 7\% growth, LCY
- Slow quarter in Prosthetics, 3\% LCY
- Strong growth in B\&S, $12 \%$ LCY


## Operations

EBITDA USD 19 m
Stable Margins

- Gross profit margin 62\%
- EBITDA margin 22\%


## Key Highlights

- Expanding sales coverage
- PROPRIO - paving the road
- Mexico facility operational


## AMERICAS Q3 2010 - EXCELLENT B\&S PERFORMANCE

## Americas 55\% of total sales

- Sales growth 11\%
- Excellent B\&S sales growth
- Increased investment in sales platform
- Successful new product launches
- Prosthetics slow quarter
- Preparing the market for PROPRIO
- Strong comparison

[^0]

## EMEA Q3 2010 - MODERATE GROWTH



## EMEA 40\% of total sales

- Sales growth 3\%
- B\&S slow growth
- New products not contributing as expected
- Discontinued product lines affecting growth
- Prosthetics growing above market growth
- Gaining market share
- Compression therapy 2\% growth

Note: All growth numbers in local currency including investments

## ASIA Q3 2010 - UNUSUAL QUARTER

## Asia 5\% of total sales

- Sales decline 1\%
- B\&S
- $\quad$ Strong sales in Australia
- Increased penetration in new markets
- Prosthetics
- Impacted by reimbursement review in Japan
- Good prospects for Q4

[^1]

## SUCCESSFUL B\&S PRODUCT PIPELINE



Techform Premium \& Standard
Formfit 45


## PROSTHETIC PRODUCT PIPELINE REMAINS STRONG





- Good overall growth
- Expanding sales coverage
- Material exchange rate differences
- Solid profits and cash flow


## INCOME STATEMENTS Q3 2010

| Income Statements (USD millions) | Q3 2010 | \% of sales | Q3 2009 | \% of sales | Change | \%change |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 87.4 | $100.0 \%$ | 84.2 | $100.0 \%$ | 3.2 | $3.8 \%$ |
| Gross profit | 54.4 | $62.3 \%$ | 51.7 | $61.4 \%$ | 2.7 | $5.2 \%$ |
| Operating expenses | -38.7 | $-44.3 \%$ | -36.8 | $-43.7 \%$ | -1.9 | $5.2 \%$ |
| Profit from operations | 15.7 | $18.0 \%$ | 14.9 | $17.7 \%$ | 0.8 | $5.4 \%$ |
| Financial income / (expenses) | -10.4 | $-11.9 \%$ | -8.2 | $-9.7 \%$ | -2.2 | $26.9 \%$ |
| Net profit | 4.0 | $4.6 \%$ | 4.8 | $5.7 \%$ | -0.8 | $-16.7 \%$ |
| EBITDA | 19.1 | $21.8 \%$ | 19.4 | $23.0 \%$ | -0.3 | $-1.5 \%$ |
| EBITDA adjusted ${ }^{*}$ | 19.7 | $22.5 \%$ | 19.4 | $23.0 \%$ | 0.3 | $1.5 \%$ |

*Adjusted for one-time items:

| USD m | Gains | Expenses | Net effect |
| :--- | ---: | ---: | ---: |
| Q3 2010 | 0 | 0.6 | 0.6 |
| Q3 2009 | 0 | 0 | 0 |

## SALES - MODERATE ORGANIC GROWTH



- Overall sales growth 7\% LCY
- Organic sales growth 4\% LCY
- Mixed performance across segments
- Outlook Q4 - soft organic growth

Note: Organic LCY growth excludes acquisitions

## SALES GROWTH BY SEGMENTS Q3 2010

| Sales by region / segments | Growth USD | Growth LCY | Organic growth LCY * |
| :--- | ---: | ---: | ---: |
| Americas | $11 \%$ | $11 \%$ | $6 \%$ |
| EMEA | $-5 \%$ | $3 \%$ | $3 \%$ |
| Asia | $1 \%$ | $-1 \%$ | $-1 \%$ |
| Total | $4 \%$ | $7 \%$ | $4 \%$ |
| Prosthetics | $0 \%$ | $3 \%$ | $3 \%$ |
| Bracing and supports | $9 \%$ | $12 \%$ | $6 \%$ |
| Compression therapy | $-5 \%$ | $5 \%$ | $2 \%$ |
| Total | $4 \%$ | $7 \%$ | $4 \%$ |
| *Excluding acquired entities |  |  |  |

## GROSS PROFIT - CONSISTENT




## OPERATING EXPENSES - STABLE



- S\&M - Expanding sales coverage
- R\&D - Stable contribution
- G\&A - Marginal increase in efficiency


## EXCHANGE RATE MOVEMENTS - VOLATILE

FINANCIAL ITEMS: NET EXCHANGE RATE DIFFERENCES


## NET PROFIT - IMPACTED BY EXCHANGE RATES



- Net profit USD 4 million
- Volatile exchange rate movements
- Material impact on financial items


## EBITDA MARGIN - 23\%




## CASH FLOW - SOLID CASH GENERATION

CASH GENERATED BY OPERATIONS



## CAPEX - BELOW BENCHMARK




## BALANCE SHEETS 30 SEPTEMBER 2010

| USD '000 | 30. Sept '10 | 31. Dec '09 |
| :--- | ---: | ---: |
| Non current assets | 434,841 | 448,446 |
| Current assets | 170,543 | 179,771 |
| Total assets | 605,384 | 628,217 |
| Stockholders' equity |  |  |
| Non current liabilities | 334,554 | 312,223 |
| Current liabilities | 196,940 | 237,045 |
| Total equity and liabilities | 73,890 | 78,949 |
| Current ratio | 605,384 | 628,217 |
| Equity ratio |  |  |
| Net interest bearing debt / EBITDA | 2.3 | 2.3 |
| Debt / EBITDA | $55 \%$ | $50 \%$ |



## FINANCIAL HIGHLIGHTS Q3 2010



- Good overall growth
- Expanding sales coverage
- Material exchange rate differences
- Solid profits and cash flow


Guidance - Management estimates LCY organic sales growth for 2010 to be within the original guided range of $4-6 \%$. EBITDA LCY organic growth is now estimated to be in the range of $5-7 \%$ for the year.

Guidance 2010

Sales growth organic (LCY): 4-6\% EBITDA growth organic (LCY): 5-7\%


## INCOME STATEMENTS Q3 2010

Life Without Limitations

| Income Statements (USD millions) | Q3 2010 | \% of sales | Q3 2009 | \% of sales | Change |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 87.4 | 100.0\% | 84.2 | 100.0\% | 3.2 | 3.8\% |
| Cost of goods sold | -33.0 | -37.7\% | -32.5 | -38.6\% | -0.5 | 1.5\% |
| Gross profit | 54.4 | 62.3\% | 51.7 | 61.4\% | 2.7 | 5.2\% |
| Other income | 0.1 | 0.1\% | 0.0 | 0.0\% | 0.1 | - |
| Sales and marketing | -23.0 | -26.3\% | -21.9 | -26.1\% | -1.1 | 5.0\% |
| Research and development | -4.7 | -5.4\% | -4.2 | -5.0\% | -0.5 | 11.9\% |
| General and administrative | -11.1 | -12.7\% | -10.7 | -12.7\% | -0.4 | 3.7\% |
| Profit from operations | 15.7 | 18.0\% | 14.9 | 17.7\% | 0.8 | 5.4\% |
| Financial income | 0.1 | 0.1\% | 0.0 | 0.1\% | 0.1 | - |
| Financial expenses | -4.0 | -4.6\% | -4.0 | -4.8\% | 0.0 | 0.0\% |
| Net exchange rate difference | -6.5 | -7.4\% | -4.2 | -5.0\% | -2.3 | 54.8\% |
| Profit before tax | 5.3 | 6.1\% | 6.7 | 8.0\% | -1.4 | -20.9\% |
| Income tax | -1.3 | -1.5\% | -1.9 | -2.3\% | 0.6 | -31.6\% |
| Net profit | 4.0 | 4.6\% | 4.8 | 5.7\% | -0.8 | -16.7\% |
|  |  |  |  |  |  |  |
| EBITDA | 19.1 | 21.8\% | 19.4 | 23.0\% | -0.3 | -1.5\% |
| EBITDA adjusted* | 19.7 | 22.5\% | 19.4 | 23.0\% | 0.3 | 1.5\% |

*Adjusted for one-time items:

|  |  |  |  |
| :--- | ---: | ---: | ---: |
| USD m | Gains | Expenses | Net effect |
| Q3 2010 | 0 | 0.6 | 0.6 |
| Q3 2009 | 0 | 0 | 0 |

## INCOME STATEMENTS YTD 2010

Life Without Limitations

| Income Statements (USD millions) | YTD 2010 | \% of sales | YTD 2009 | \% of sales | Change |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 263.9 | 100.0\% | 242.7 | 100.0\% | 21.2 | 8.7\% |
| Cost of goods sold | -99.8 | -37.8\% | -93.9 | -38.7\% | -5.9 | 6.3\% |
| Gross profit | 164.1 | 62.2\% | 148.8 | 61.3\% | 15.3 | 10.3\% |
| Other income | 1.6 | 0.6\% | 0.4 | 0.2\% | 1.2 | 300.0\% |
| Sales and marketing | -71.4 | -27.0\% | -69.1 | -28.5\% | -2.3 | 3.3\% |
| Research and development | -14.6 | -5.5\% | -13.9 | -5.7\% | -0.7 | 5.0\% |
| General and administrative | -33.8 | -12.8\% | -31.6 | -13.0\% | -2.2 | 7.0\% |
| Profit from operations | 45.9 | 17.4\% | 34.5 | 14.2\% | 11.4 | 33.0\% |
| Financial income | 0.3 | 0.1\% | 0.2 | 0.1\% | 0.1 | 50.0\% |
| Financial expenses | -11.7 | -4.4\% | -11.5 | -4.7\% | -0.2 | 1.7\% |
| Net exchange rate difference | 1.9 | 0.7\% | -3.5 | -1.4\% | 5.4 | -154.3\% |
| Profit before tax | 36.4 | 13.8\% | 19.7 | 8.1\% | 16.7 | 84.8\% |
| Income tax | -9.1 | -3.4\% | -5.0 | -2.1\% | -4.1 | 82.0\% |
| Net profit | 27.3 | 10.3\% | 14.7 | 6.1\% | 12.6 | 85.7\% |
|  |  |  |  |  |  |  |
| EBITDA | 56.5 | 21.4\% | 49.2 | 20.3\% | 7.3 | 14.8\% |
| EBITDA adjusted* | 56.3 | 21.3\% | 50.9 | 21.0\% | 5.4 | 10.6\% |

*Adjusted for one-time items:

| USD m | Gains | Expenses | Net effect |
| :--- | ---: | ---: | ---: |
| 2010 | -1.3 | 1.1 | -0.2 |
| 2009 | 0 | 1.7 | 1.7 |




[^0]:    Note: All growth numbers in local currency including investments

[^1]:    Note: All growth numbers in local currency

